Serving 500+ biopharmaceutical companies globally:
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
Serving 500+ biopharmaceutical companies globally:
Generated: September 20, 2017
What is the competitive landscape for ARBOR PHARMS LLC, and when can generic versions of ARBOR PHARMS LLC drugs launch?
ARBOR PHARMS LLC has twenty-one approved drugs.| Patents: | 19 |
| Tradenames: | 22 |
| Ingredients: | 14 |
| NDAs: | 21 |
Export unavailable in trial.
Subscribe for complete access.
Export unavailable in trial.
Subscribe for complete access.
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 9,150,503 | Crystalline form of .gamma.-aminobutyric acid analog | ► Subscribe | |||||||||||||||||||||||||||
| 6,833,140 | Orally administered dosage forms of GABA analog prodrugs having reduced toxicity | ► Subscribe | |||||||||||||||||||||||||||
| 7,423,169 | Methods for synthesis of acyloxyalkyl derivatives of GABA analogs | ► Subscribe | |||||||||||||||||||||||||||
| 8,906,412 | GABA analog prodrug sustained release oral dosage forms | ► Subscribe | |||||||||||||||||||||||||||
| 7,232,924 | Methods for synthesis of acyloxyalkyl derivatives of GABA analogs | ► Subscribe | |||||||||||||||||||||||||||
| 7,186,855 | Prodrugs of GABA analogs, compositions and uses thereof | ► Subscribe | |||||||||||||||||||||||||||
| 7,875,637 | Benzimidazole derivative and use as a II receptor antagonist | ► Subscribe | |||||||||||||||||||||||||||
| 8,367,722 | Methods of using prodrugs of pregabalin | ► Subscribe | |||||||||||||||||||||||||||
| 9,238,616 | Prodrugs of gaba analogs, compositions and uses thereof | ► Subscribe | |||||||||||||||||||||||||||
| 6,972,341 | Prodrugs of GABA analogs, compositions and uses thereof | ► Subscribe | |||||||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
| Country | Document Number | Estimated Expiration | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Israel | 202603 | ► Subscribe | |||||||||||||||||||||||||||
| Israel | 201188 | ► Subscribe | |||||||||||||||||||||||||||
| Morocco | 28478 | ► Subscribe | |||||||||||||||||||||||||||
| South Korea | 20040016882 | ► Subscribe | |||||||||||||||||||||||||||
| China | 1946717 | ► Subscribe | |||||||||||||||||||||||||||
| Canada | 2584338 | ► Subscribe | |||||||||||||||||||||||||||
| Cyprus | 1109610 | ► Subscribe | |||||||||||||||||||||||||||
| Portugal | 1404324 | ► Subscribe | |||||||||||||||||||||||||||
| World Intellectual Property Organization (WIPO) | 2008137699 | ► Subscribe | |||||||||||||||||||||||||||
| Norway | 20035474 | ► Subscribe | |||||||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws,
it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description | ||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2015 00045 | Denmark | ► Subscribe | PRODUCT NAME: IVERMECTIN, 22, 23-DIHYDROAVERMECTINB1A + 22,23-DIHRODROAVERMECTIN B1B FOR USE IN THE TREATMNET OF RESACEA; NAT. REG. NO/DATE: 54123 20150422; FIRST REG. NO/DATE: MT MA 117/01101 20150402 | ||||||||||||||||||||||||||
| 6 | Finland | ► Subscribe | |||||||||||||||||||||||||||
| 1 5004-2012 | Slovakia | ► Subscribe | PRODUCT NAME: AZILSARTAN MEDOXOMIL; REGISTRATION NO/DATE: EU/1/11/734/001 - EU/1/11/735/011 20111207 | ||||||||||||||||||||||||||
| 1718641/01 | Switzerland | ► Subscribe | PRODUCT NAME: AZILSARTAN MEDOXOMIL; REGISTRATION NO/DATE: SWISSMEDIC 62158 31.08.2012 | ||||||||||||||||||||||||||
| C/GB01/013 | United Kingdom | ► Subscribe | PRODUCT NAME: N,N'-BIS(2-CHLOROETHYL)-N-NITROSO-UREA (CARMUSTINE) COMBINED WITH A POLYANHYDRIDE HAVING A WEIGHT AVERAGE MOLECULAR WEIGHT OF GREATER THAN 20,000 PREPARED BY THE POLYCONDENSATION OF: (I) 4,4'-(TRIMETHYLENEDIOXY)-DIBENZOIC ACID; AND (II) SEBACIC ACID (POLI; REGISTERED: FR 561 907-5 19990105; UK PL 00012/0337 20000928 | ||||||||||||||||||||||||||
| C0069 | France | ► Subscribe | PRODUCT NAME: IVERMECTINE; NAT. REGISTRATION NO/DATE: NL 44511 20150721; FIRST REGISTRATION: MT - MA 117/01101 20150402 | ||||||||||||||||||||||||||
| 2015000079 | Germany | ► Subscribe | PRODUCT NAME: IVERMECTIN ZU SEINER VERWENDUNG FUER DIE BEHANDLUNG VON ROSAZEA; NAT. REGISTRATION NO/DATE: 92429.00.00 20150429; FIRST REGISTRATION: MALTA MA 117/01101 20150402 | ||||||||||||||||||||||||||
| 2015033 | Lithuania | ► Subscribe | PRODUCT NAME: IVERMECTINUM; NAT. REGISTRATION NO/DATE: LT/1/15/3726/001 - LT/1/15/3726/005 20150513; FIRST REGISTRATION: MA117/01101 20150402 | ||||||||||||||||||||||||||
| 0802 | Netherlands | ► Subscribe | PRODUCT NAME: AZILSARTAN MEDOXOMIL EN CHLOORTALIDON; NATIONAL REGISTRATION NO/DATE: RVG116387 20151125; FIRST REGISTRATION: CH 6314502 20141028 | ||||||||||||||||||||||||||
| 0120004 00052 | Estonia | ► Subscribe | PRODUCT NAME: EDARBI - ASILSARTAANMEDOKSOMIIL;REG NO/DATE: C(2011) 9280 FINAL 07.12.2011 | ||||||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
Serving 500+ biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Follow DrugPatentWatch:
Join the 22,676 others who get our Drug Patent Expiration Alerts:
